
Evommune Inks Up to $1.1bn Deal for Hinova Autoimmune Drug
Evommune (EVMN) has licensed rights to an experimental autoimmune disease treatment from China’s Hinova Pharmaceuticals (688302.SS) in a deal worth up to about $1.1bn in milestone payments. Under the agreement, the California-based drug…